- 1、本文档共42页,可阅读全部内容。
- 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
- 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
乳腺癌TKI治疗ppt课件
Sunitinib in Combination with Docetaxel vs. Docetaxel Alone for the First-line Treatment of Advanced Breast Cancer Endpoints and Statistical Hypothesis Primary endpoint: PFS Hypothesis: 50% increase in median PFS (from 6 to 9 months) in ITT population (independent central review), based on 285 events, power of 90%, alpha error 0.025, one sided log-rank test Secondary endpoints PFS (investigator assessment) ORR, duration of response OS Safety Median follow-up: 18.0 months (95% CI: 17.6?18.4) Fatalities Phase 3 Trial of Sunitinib in Combination with Capecitabine vs. Capecitabine in Previously Treated Advanced Breast Cancer 多靶点TKI治疗 * ORR: 1-sided P value = 0.490 * ORR: 1-sided P value = 0.189 * * * Overall Response in Patients with Measurable Disease (Investigator Assessment) Response parameter SU + CAP n=206 CAP n=201 Objective response rate,* % 95% exact CI 27 21?34 22 17?29 Complete response, % 0 1 Partial response,% 27 21 Stable disease, % 46 50 Stable disease ≥26 weeks, % 13 14 Median duration of response, months, 95% CI 5.7 4.3?6.9 7.6 6.5?9.9 *% CR + PR Conclusions The study did not meet its primary endpoint Sunitinib in combination with capecitabine did not improve efficacy compared with capecitabine alone The frequency of AEs was higher with sunitinib and capecitabine than with capecitabine alone Treatment discontinuations and dosing modifications occurred more frequently in the combination arm The sunitinib?capecitabine regimen evaluated in this study is not recommended for second- or third-line treatment of patients with ABC 拉帕替尼 Lapatinib oral tyrosine kinase inhibitor of ErbB1 and ErbB2 Blocks signaling through EGFR and HER2 homodimers and heterodimers May also prevent signaling between ErbB1/ErbB2 and other ErbB family members PTEN Lapatinib P13K pAkt Ras Raf pErk Shc Grb2 So8 Phospholipid cell membrane 到疾病进展时间(ITT Population) 70 20 40 60 80 0 100 10 20 30 40 50 60 0 Time (weeks) Patients Progression Free* (%) Lap + Cap Cap 病例数, n 160 161 Med
您可能关注的文档
- 三菱汽车MUT-III故障诊断仪使用培训ppt课件.ppt
- 上海大众-汽车高级销售技巧培训ppt课件.ppt
- 上海大众7档双离合变速箱0AM实践培训ppt课件.ppt
- 上海大众NMS-车身技术培训ppt课件.ppt
- 上海大众仪表盘培训ppt课件.ppt
- 上海大众Tiguan途观四驱培训ppt课件.ppt
- 上海大众发动机EDC控制系统培训ppt课件.ppt
- 上海大众汽车电器故障诊断培训ppt课件.ppt
- 上海大众新款双离合变速箱DQ380技术培训ppt课件.ppt
- 上海大众空调系统培训ppt课件.ppt
- 江苏省灌云高级中学2023-2024学年高三上学期第一次月考地理试题含答案.docx
- 备战2024年高考物理一轮重难点复习 第十三章 近代物理.docx
- 江苏省高邮市一中2021-2022学年高三上学期第一次月考语文试题(原卷版).docx
- 江苏省华罗庚中学2023-2024学年高三上学期12月阶段检测数学试卷含答案.docx
- 江苏省海门中学2023-2024学年高三上学期第一次调研考试地理试题及答案.docx
- 备战2024年高考物理一轮重难点复习 第九章 恒定电流.docx
- 江苏省高邮市2023-2024学年高三下学期3月学情调研数学试题含答案.docx
- 备战2024年高考物理一轮重难点复习 实验十一:探究影响感应电流方向的因素.docx
- 备战2024年高考物理一轮重难点复习 实验三:验证平行四边形定则.docx
- 备战2024年高考物理一轮重难点复习 第十四章 光.docx
文档评论(0)